menu
    • menu

    Company profile for LIPAC Oncology

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    LIPAC Oncology is a clinical stage pharmaceutical company employing LiPax,™ its proprietary proliposomal intracavitary paclitaxel drug delivery platform, to enhance and reformulate proven cancer drugs into more effective treatments. LiPax, a locally delivered formulation of paclitaxel, is being developed for the intravesical treatment of non-muscle invasive bladder cancer (NMIBC) and other intracavitary cancer indications. ...
    LIPAC Oncology is a clinical stage pharmaceutical company employing LiPax,™ its proprietary proliposomal intracavitary paclitaxel drug delivery platform, to enhance and reformulate proven cancer drugs into more effective treatments. LiPax, a locally delivered formulation of paclitaxel, is being developed for the intravesical treatment of non-muscle invasive bladder cancer (NMIBC) and other intracavitary cancer indications. LiPax is a next generation localized proliposomal formulation of paclitaxel that targets numerous solid tumor carcinomas that are difficult to treat.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LIPAC OncologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3670 West Temple Avenue, Suite 270 Pomona, CA 91768
    Telephone
    Telephone
    (909) 595-0500
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lipaconcology.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    LIPAC Oncology to Present Two-year Data for Phase 1/2a Study of LiPax
    LIPAC Oncology to Present Two-year Data for Phase 1/2a Study of LiPax

    15 Nov 2021

    // BIOSPACE

    https://www.biospace.com/article/releases/lipac-oncology-to-present-two-year-data-for-phase-1-2a-study-of-lipax-at-the-22nd-annual-meeting-of-the-society-of-urologic-oncology/?s=105

    BIOSPACE
    15 Nov 2021
    Share Share
    LIPAC Oncology Announces Positive Data on LiPax
    LIPAC Oncology Announces Positive Data on LiPax

    09 Jun 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/lipac-oncology-announces-two-year-recurrence-free-survival-data-for-phase-12a-study-of-lipax-in-patients-with-non-muscle-invasive-bladder-cancer-301308532.html

    PRNEWSWIRE
    09 Jun 2021
    Share Share
    LIPAC Oncology Announces Successful Type B Meeting with the U.S. FDA
    LIPAC Oncology Announces Successful Type B Meeting with the U.S. FDA

    29 Apr 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/lipac-oncology-announces-successful-type-b-meeting-with-the-us-fda-for-the-study-of-lipax-for-non-muscle-invasive-bladder-cancer-301279794.html

    PRNEWSWIRE
    29 Apr 2021
    Share Share
    LIPAC Oncology Announces Major Partnering Milestone Achieved in its Agreement
    LIPAC Oncology Announces Major Partnering Milestone Achieved in its Agreement

    10 Dec 2020

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/lipac-oncology-announces-major-partnering-milestone-achieved-in-its-agreement-1611560321.pdf

    PRESS RELEASE
    10 Dec 2020
    Share Share
    LIPAC Oncology Announces Completion of Phase 2A Clinical Trial of LiPax
    LIPAC Oncology Announces Completion of Phase 2A Clinical Trial of LiPax

    08 Sep 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/lipac-oncology-announces-completion-of-phase-2a-clinical-trial-of-lipax-in-patients-with-non-muscle-invasive-bladder-cancer/

    BIOSPACE
    08 Sep 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search